Summary.-Forty-one adult patients with acute myelogenous leukaemia entered remission induced by daunorubicin and cytosine arabinoside, and subsequently received 6 weeks' consolidation therapy with cyclophosphamide plus 6-thioguanine. They were then randomized to either immunotherapy consisting of intradermal BCG plus allogeneic cells or to "no maintenance". Patients receiving immunotherapy had significantly longer remission (P=0.039) and survival from remission (P=0.044) as assessed by the log-rank test. The median duration of first remission for 21 patients receiving immunotherapy was 35-14 weeks, compared with 19-71 weeks for 20 patients on no maintenance, and the median survival from remission was doubled in patients receiving immunotherapy. The value of adequate consolidation chemotherapy is confirmed by the comparatively long first remissions in both groups compared with our previous trials, whilst avoidance of maintenance chemotherapy possibly allowed frequent second remissions and similar post-relapse survival in patients from both treatment arms.
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FOLLOWING Mathe&s (1969) encouraging results with immunotherapy in acute lymphoblastic leukaemia, and a similar potential later shown in acute myelogenous leukaemia (Powles et al., 1971) we initiated a pilot study of active immunotherapy used alone during remission in adult patients with acute myelogenous leukaemia (AML). This study, which showed easy reinduction with consequent prolongation of survival after relapse (Freeman et al., 1973) was later followed in Manchester by a randomized trial under the aegis of the MRC which compared immunotherapy with a combination of immunotherapy and chemotherapy (Harris et al., 1978a) . This trial again suggested that immunotherapy (when given without maintenance chemotherapy) improved post-relapse survival. However, a halving of first remission length compared with the pilot study was attributed to the omission of cytoreduction from the MRC protocol. It was also unclear whether immunotherapy itself was therapeutically beneficial or whether its apparent advantages were due to the avoidance of drug resistance induced by maintenance chemotherapy. We designed our present trial to remove these uncertainties. Consolidation chemotherapy was reintroduced following remission induced identically. Patients were then randomized to either immunotherapy alone or a "no-maintenance arm". This trial protocol allowed us for the first time to assess the value of immunotherapy uncomplicated by simultaneous maintenance chemotherapy. intervals. Marrows were reported on by a number of different individuals, the majority of whom were not aware of the treatment arm to which the patient had been randomized. Details of induction, criteria for remission and relapse and administration of immunotherapy are described elsewhere (Freeman et al., 1973; Harris et al., 1978a) .
Statistical methods.-Although conventional median values are given, Kaplan-Meier life tables and log-rank analyses were used to test the statistical significance of differences in remission length and survival, using exact variance calculations without continuity corrections (Peto et al., 1977 The difference between RI and RO now believe interferes with the effects of patients is not significant (X2 = 089, P = immunotherapy.
We designed our third trial so as to overcome these problems. Firstly, we reintroduced a consolidation phase after induction chemotherapy, in an attempt to further reduce leukaemic cell mass. We then randomized patients to one of 2 therapeutic arms; immunotherapy alone (RI) or "no maintenance" (RO). It was then possible to assess the value of immunotherapy in patients in remission with minimum leukaemic cell mass and uncomplicated by simultaneous chemotherapy. Over a follow-up period varying from 10 months to 4 years, immunotherapy patients in this trial have had significantly longer remissions and survival than patients receiving no maintenance treatment. It is also noteworthy that there was no overt CNS involvement in patients on immunotherapy, compared with 3 RO patients with leukaemic CNS disease, although Peto et al. (1977) have indicated the difficulties in the analysis of CNS involvement. Our immunotherapy patients fared as well as those of Powles et al. (1977b) who used a "superior" form of immunotherapy (BCG and cells mixed together), both in terms of length of first remission and in the proportion remaining in remission for more than 2 years. It is particularly encouraging that the significant differences between our RI and the RO patients appear to be genuine, and not due to unusually poor remission lengths or durations of survival in the controls. For example, the RO median remission length of almost 20 weeks is comparable with chemotherapy medians in other studies (Reizenstein et al., 1978; MRC, 1978) while the median of 22 weeks for survival after relapse in the RO group is similar to that reported by the MRC (1978) for patients receiving immunotherapy plus maintenance chemotherapy, and is better than chemotherapy medians (MRC, 1978 (MRC, , 1979 .
In this trial second-remission rates and post-relapse survival are similar in RO and RI patients, confirming our original suggestion (Freeman et al., 1973 ) that the poor post-relapse performance of RI plus chemotherapy (referred to as I + C) compared with RI may have been partly due to mnaintenance chemotherapy. Indeed, the results of our present (third) trial suggest that maintenance chemotherapy may worsen the outlook for patients who relapse and should, unless otherwise indicated, be omitted. Thus, although RI patients had significantly longer first remissions and survival than RO patients, there was no significant difference between RI and RO in terms of post-relapse survival or second-remission rates, whilst both groups of patients have done better than would be expected from the published data on post-relapse performance of patients receiving maintenance chemotherapy (Powles et al., 1977a; Whittaker & Slater, 1977; Gale & Cline, 1977; MRC, 1978 MRC, , 1979 . We suggest that chemotherapy seems unnecessary for maintenance if adequate induction and consolidation treatment has been given, and is better reserved for reinduction after first relapse, detected early by monthly marrow examination whilst the leukaemic cell mass is still small (Harris et al., 1978a) . In our opinion, based on 8 years' experience of immunotherapy in AML, there is no ethical objection to the omission of maintenance chemotherapy, so long as no form of treatment is available which will selectively ablate all leukaemic cells.
The value of consolidation chemotherapy emerges from a comparison of this with our earlier trials. Thus, first-remission length was reduced to 11-5 weeks in the immunotherapy-alone arm of our second trial (Harris et al., 1978a) in which consolidation chemotherapy was not used, and should be compared with our trials which did include consolidation, notably the superior results of 23 weeks in the first trial (Freeman et al., 1973) (Harris et al., 1977 (Harris et al., . 1978b 
